Melhores Câncer do intestino delgado médicos em Israel - TOP-20 médicos

A Dra. Pelles Sharon é especialista em tratamentos oncológicos avançados, incluindo cancro do intestino delgado, no Sourasky Medical Center (Ichilov).

• Oferecer uma gama de tratamentos cirúrgicos e não cirúrgicos, como a terapia SIRT e HIPEC
• Ser ativa em investigação clínica, contribuindo para estudos sobre as atitudes de pacientes oncológicos
• Fornecer opções de imunoterapia e terapia alvo
• Ser especialista em cirurgias de cancro do fígado e do pâncreas

O Prof. Merimsky lidera a Unidade de Oncologia de Tecidos Moles e Ósseos no Sourasky Medical Center, especializando-se em tumores raros, como o cancro do intestino delgado.

• Mais de 25 anos de experiência em oncologia, com foco em sarcomas e cancros raros
• Investigador sénior no Instituto Weizmann e na Universidade de Tel-Aviv
• Membro da Faculdade de Sarcomas da ESMO e do comité de ética da IASLC
• Formado no Institut Gustave Roussy, em Paris – o principal centro de sarcomas da Europa

Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.

He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.

He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.

Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.

He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.

Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.

Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.

MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.

Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

O Dr. Wolf chefia a Divisão de Oncologia Médica do Sourasky Medical Center, um dos maiores e mais proeminentes hospitais de Israel.

• Chefiar a divisão que trata cancros gastrointestinais complexos
• Possuir licenciaturas e formação extensiva em oncologia médica
• Ter experiência na gestão de casos de cancro raros, como os do intestino delgado
• Trabalhar num grande centro médico académico para protocolos de tratamento avançados

O Dr. Greenberg é um renomado especialista em cirurgia de Whipple – uma operação fundamental para o cancro do intestino delgado – e chefia o Departamento de Cirurgia Colorretal no Sourasky Medical Center.

• Mais de 20 anos de experiência como cirurgião abdominal
• Realizar técnicas cirúrgicas abertas e minimamente invasivas
• Liderar um departamento dedicado num grande hospital terciário

Diretor de internação oncológica no Tel Aviv Medical Center – O Dr. Stepfansky lidera uma unidade de oncologia especializada com foco em cancro do intestino delgado.

• Mais de 25 anos de experiência em oncologia e medicina interna
• Investigador principal e secundário em ensaios clínicos de fase 1-3
• Formado no Tel Aviv Medical Center, um dos principais hospitais de Israel
• Especializar-se no diagnóstico e tratamento do cancro do intestino delgado

O Dr. Klauzner é reconhecido como um dos melhores cirurgiões de Whipple em Israel – um procedimento complexo para tumores no sistema digestivo. Ele chefia o departamento de cirurgia do Sourasky Medical Center (Ichilov).

• Especializar-se em cirurgias de cancro gastrointestinal, pancreático e colorretal
• Mais de 45 anos de experiência cirúrgica
• Ocupar o cargo sénior de Presidente de Cirurgia

33 anos de especialização em oncologia e radioterapia – O Dr. Auala Hubert chefia o Centro de Cancro Gastrointestinal do Hadassah Medical Center.

• Certificado em oncologia e radioterapia
• Graduado pelo Hospital Universitário Hadassah
• Fluente em inglês e hebraico
• Membro de múltiplas associações de oncologia

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Vice-Chefe do Departamento de Oncologia do Rambam Medical Center – um papel de liderança no tratamento do cancro.

• Especializar-se no tratamento do cancro do intestino delgado
• Trabalhar num centro médico de primeira linha em Israel
• Ocupar um cargo de liderança em oncologia

O Dr. Alexander Beny é Diretor do Serviço de Malignidade Gastrointestinal no Rambam Medical Center, especializado em cancro do intestino delgado.

• Oncologista certificado com o Exame do Conselho da Comunidade Europeia em Medicina
• Chefiar a clínica de Oncologia Gastrointestinal no Rambam Medical Center
• Formado em técnicas modernas de Braquiterapia através do curso ESTRO
• Experiente em abordagens de oncologia médica e radioterápica

O Dr. Gutman é um oncocirurgião especializado em cancro do intestino delgado no Assuta Medical Center.

• Especializar-se em oncologia cirúrgica com experiência em casos de intestino delgado
• Trabalhar no Assuta Medical Center – um hospital oncológico de referência
• Fornecer planos de tratamento personalizados para cada paciente

Especialista em cirurgia endoscópica – O Dr. Kashtan concentra-se em técnicas minimamente invasivas para o cancro do intestino delgado no Assuta Medical Center.

• Formado em procedimentos endoscópicos avançados
• Trabalhar num dos principais centros de oncologia de Israel
• Especialização no tratamento do cancro do intestino delgado